Navigation Links
Eddingpharm Acquired Global Rights to Oncology Assets, Including Telatinib, from ACT Biotech
Date:1/8/2014

SHANGHAI, Jan. 8, 2014 /PRNewswire/ -- Eddingpharm today announced that an asset purchase agreement (APA) has been signed with ACT Biotech, Inc. (ACT Biotech), a biopharmaceutical company based in the United States. Eddingpharm acquired worldwide rights to three small molecule drug assets (Telatinib, ACTB1003, and ACTB1010) and other molecules from ACT Biotech. Eddingpharm made an upfront payment to ACT Biotech upon the closing of the transactions contemplated under the APA. ACT Biotech is also eligible to receive clinical, regulatory, and commercial milestone payments. The total consideration, including the upfront payment, may reach up to U.S. $95 million.

The lead asset,Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer. The other two programs ACTB1003 (FGFR/VEGFR2 inhibitor) and ACTB1010 (Aurora kinases inhibitor) are in Phase I-ready and preclinical stages, respectively. Eddingpharm plans to initiate trials for Telatinib in China and continue the development that ACT Biotech started in the U.S. Eddingpharm also intends to take the other two assets into clinical development in either the U.S. or China.

Eddingpharm founder and CEO Xin Ni commented, "Eddingpharm is pleased to expand its oncology portfolio by acquiring global rights to these three promising compounds. We look forward to resuming ACT Biotech's work by advancing these important drugs to the next phase of trials in the U.S., China, and beyond."

This transaction represents the next step in Eddingpharm's growth strategy and commitment to oncology. Owning the global rights to these innovative products will allow Eddingpharm to optimize its development strategies for China and the rest of the world.

Bernard Peperstraete, MD, Acting President and Chief Executive Officer of ACT Biotech commented, "We believe that this transaction represents an attractive opportunity for ACT Biotech, its stockholders and for cancer patients, and we are delighted that ACT's promising oncology portfolio will be further developed by such a strong and internationally well-positioned partner." John Costantino, managing partner at NGN Capital, ACT Biotech's lead investor, noted, "Eddingpharm's experience in commercializing oncology products promises to accelerate and further unlock the full potential of these potent cancer compounds."

Purchased Assets

Telatinib
Telatinib, is a potent and selective small molecule VEGFR inhibitor ready for Phase III in gastric cancer, a leading cause of cancer-related death in China. Telatinib stands out in the well-validated VEGFR space for its manageable safety profile and promising objective response rates across the 300 patients treated to this point. Telatinib is currently ready for Phase III with trial design supported by the FDA and EMA, and a Special Protocol Assessment (SPA) was granted by the FDA.

ACTB1003
Phase I-ready ACTB1003 inhibits both FGFR and VEGFR2. The asset has a strong pharmacological profile.

ACTB1010
ACTB1010 is an Aurora kinase inhibitor in preclinical development.

About Eddingpharm
Founded in 2001, Eddingpharm is a fast growing specialty pharmaceutical company in the Chinese market, committed to actively introducing quality products into China's pharmaceutical market. The Company focuses on the development and promotion of pharmaceutical products in four therapeutic areas: clinical nutrition, oncology, antibiotics and respiratory system. Eddingpharm has established long-term cooperative relationships with a number of multinational pharmaceutical companies and overseas specialty pharmaceutical companies, and has built up a competitive product portfolio and pipeline in the four major therapeutic areas. Eddingpharm recently established its U.S. affiliate and set up a product development team with R&D capabilities in Los Angeles, CA, USA, to coordinate and communicate with leading global R&D institutions and explore opportunities for introducing innovative pharmaceutical products in China. The Company currently employs over 700 people.

About ACT Biotech
ACT Biotech, Inc., is a biopharmaceutical company that was founded in 2008. Prior to Eddingpharm's asset acquisition, ACT Biotech focused on the development and commercialization of highly targeted, orally available cancer drugs. ACT Biotech's lead product candidate was Telatinib. Telatinib demonstrated robust antitumor activity with a solid safety profile in a Phase 2 clinical trial in stomach cancer. Telatinib has also shown encouraging antitumor activity in a broad clinical trial program as a single agent in colorectal, kidney, stomach and liver cancers. ACT Biotech's product candidates were originally developed at Bayer Pharmaceuticals and were licensed by ACT Biotech following Bayer's merger with Schering AG. ACT Biotech is backed by NGN Capital and Sobera Capital GmbH.

Eddingpharm Contacts:

United States:
Dr. Xiaoming Zou
Chief Business Officer
(805) 379-9880
zouxm@eddingpharm.com

Shanghai:
Ms. Eva Bao
Public Relations
+86 21 3175 7995
baoxiao@eddingpharm.com

ACT Biotech Contact:

Bernard Peperstraete, M.D.
Acting President and Chief Executive Officer
c/o NGN Capital
369 Lexington Ave., 17th Floor
New York, NY 10017
USA
+1 (212) 972-0077
bpeperstraete@actbiotech.com


'/>"/>
SOURCE Eddingpharm
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Syndax and Eddingpharm Enter into a License Agreement Giving Eddingpharm Rights to Commercialize Entinostat in China and Other Asian Countries
2. Texas Childrens Center for Preventive Cardiology is the only center in Texas offering multidisciplinary, specialized care for children at risk for acquired heart disease
3. MidCap Financial Acquired by an Entity Managed by Apollo Global Management
4. Israeli Medical Device Company FlowSense Acquired by Baxter
5. Hospital Acquired Infection Control Market: Sterilization, Disinfection, Testing and Treatment
6. Rochester Medical to be Acquired by C. R. Bard for Approximately $262 Million
7. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
8. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
9. Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential
10. Founder of Nestle-Acquired Company Joins Prismic Pharmaceuticals
11. Young Innovations Announces Definitive Agreement to be Acquired by Linden Capital Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/9/2017)... NEW YORK , Sept. 8, 2017 ... largest independent supplier of medical equipment, supplies, drugs, ... that it has entered into an agreement to acquire ... surgical equipment based in Holtsville, New York ... which specializes in supplying new and emerging medical practices, ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
Breaking Medicine Technology:
(Date:9/19/2017)... Camp Pendleton, California (PRWEB) , ... September 19, 2017 , ... ... service members and their families, announces the release of a series of videos and ... suicide epidemic for service members in the United States as part of its ongoing ...
(Date:9/19/2017)... ... September 19, 2017 , ... Public outrage over the toxins that exist in ... ears, leaving the water industry itself to research, develop and ultimately supply consumers with ... in the field of natural alkaline water technologies, water filtration ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... supplement developed by a neurosurgeon, has received a big bump in sales ... Brain Booster is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, ...
(Date:9/19/2017)... ... 19, 2017 , ... First Choice Emergency Room , the largest network ... the new Medical Director of its Pflugerville- FM 685 facility. , “We are ... Pflugerville- FM 685 location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First ...
(Date:9/19/2017)... ... 19, 2017 , ... When it comes to household safety, there are few ... how to keep babies and toddlers safe, and there's no better time for companies ... Time to Check Labels, Brands that sell all kinds of common consumer products should ...
Breaking Medicine News(10 mins):